Immunophenotyping of acute lymphoblastic leukemia in pediatric patients by three-color flow cytometric analysis.
Pornthep Tiensiwakul, T Lertlum, Issarang Nuchprayoon, Panya Seksarn
Abstract
Pornthep Tiensiwakul, T Lertlum, Issarang Nuchprayoon, Panya Seksarn
Abstract
Immunophenotyping of acute lymphoblastic leukemia (ALL) in children using three-color flow cytometry was carried out at Chulalongkorn Hospital, Bangkok, Thailand. Of 38 patients with acute lymphoblastic leukemia, 65.8% were identified as common ALL, 15.8% were B-ALL, and 18.4% were T-ALL. Of these 38 cases, there were 4 cases of infantile leukemia. Relapsed cases of leukemia were found most in B-ALL up to 3 out of 6 cases and to a lesser extent in T-ALL (1 of 7 cases) and c-ALL (1 of 25 cases). Our data showed the CD markers expression for common ALL (c-ALL) were CD19+/10+ (100%), CD20+ (24%), CD22+ (100%), HLA-DR+ (70.1%), and CD34+ (58.8%). CD markers expression for B-ALL were CD19+ (100%), CD20+ (33.3%), CD22+ (80%), and HLA-DR+ (80%). CD markers expression for T-ALL were CD3+ (42.9%), CD5+ (100%), CD7+ (85.7%). Myeloid aberrant expressions were found in c-ALL (25-37.5%), B-ALL (20%), and T-ALL (14.3%). The significance of the aberration is discussed. The immunophenotyping classification of ALL as c-ALL, B-ALL, and T-ALL is useful in prognosis and treatment.
OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Immunophenotyping of acute lymphoblastic leukemia (ALL) in children using three-color flow cytometry was carried out at Chulalongkorn Hospital, Bangkok, Thailand. Of 38 patients with acute lymphoblastic leukemia, 65.8% were identified as common ALL, 15.8% were B-ALL, and 18.4% were T-ALL. Of these 38 cases, there were 4 cases of infantile leukemia. Relapsed cases of leukemia were found most in B-ALL up to 3 out of 6 cases and to a lesser extent in T-ALL (1 of 7 cases) and c-ALL (1 of 25 cases). Our data showed the CD markers expression for common ALL (c-ALL) were CD19+/10+ (100%), CD20+ (24%), CD22+ (100%), HLA-DR+ (70.1%), and CD34+ (58.8%). CD markers expression for B-ALL were CD19+ (100%), CD20+ (33.3%), CD22+ (80%), and HLA-DR+ (80%). CD markers expression for T-ALL were CD3+ (42.9%), CD5+ (100%), CD7+ (85.7%). Myeloid aberrant expressions were found in c-ALL (25-37.5%), B-ALL (20%), and T-ALL (14.3%). The significance of the aberration is discussed. The immunophenotyping classification of ALL as c-ALL, B-ALL, and T-ALL is useful in prognosis and treatment.
Key concepts: Immunophenotyping, Medicine, CD20, Leukemia, CD19, Flow cytometry, Myeloid leukemia, CD34